期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 22, 期 6, 页码 982-990出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2016.01.013
关键词
Acute myelogenous leukemia; Allogeneic hematopoietic stem; cell transplantation; FLT3; FLT3-ITD; Tyrosine kinase inhibitor
资金
- Novartis
- Astellas
- Arog
- Ambit Pharmaceuticals
- Novartis Pharmaceuticals Corporation
- Boehringer Ingelheim
In recent years, allogeneic hematopoietic stem cell transplantation (allo-HSCT) has become increasingly common in patients with acute myelogenous leukemia (AML) due to improved donor availability and the use of nonmyeloablative regimens. However, despite the potential clinical gains with allo-HSCT, the post transplantation outcomes for many patients, especially those with high-risk disease, remain dismal. Patients with AML who have internal tandem duplication mutations in the tyrosine kinase receptor FLT3 (FLT3-ITD) face particularly poor outcomes, even after allo-HSCT, which appears to only partially mitigate the poor prognosis associated with this mutation. Experimental treatments to reduce the likelihood of relapse and improve survival following allo-HSCT include maintenance with FLT3-specific tyrosine kinase inhibitors (TKIs), several of which are currently being evaluated in clinical studies. Preliminary data and case reports suggest that FLT3 TKIs can be effective in the post-transplantation setting, particularly for patients with FLT3-ITD mutations. Improvements in donor matching, transplantation procedures, and supportive care have allowed a greater number of patients to undergo allo-HSCT than ever before. For these patients, it is essential to identify effective post-transplantation therapies to reduce the risk of relapse and improve disease-free survival. (C) 2016 American Society for Blood and Marrow Transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据